Skip to main content

Table 1 Summary of study characteristics

From: Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis

Study characteristics Number of studiesa (n = 299) Percentage of studies
Year of publication
 1985–1989 3 1.00
 1990–1994 73 24.41
 1995–1999 104 34.78
 2000–2004 50 16.72
 2005–2009 34 11.37
 2010–2015 35 11.71
Geographic region
 Europe 124 41.47
 North America 79 26.42
 Asia 65 21.74
 Multi-continent 19 6.35
 South America 4 1.34
 Africa 2 0.67
 Australia 0 0.00
 Not reported 6 2.01
Study design
 RCT 246 82.27
 NRCT 33 11.04
 CBA 1 0.33
 Cohort 19 6.35
Study conduct period
 1980–1989 17 5.69
 1990–1999 69 23.08
 2000–2009 40 13.38
 2010–2013 12 4.01
 Not reported 161 53.85
Duration of follow-upb
 1 81 27.1
 2 10 3.3
 3 25 8.4
 4 10 3.3
 5 73 24.4
 6 19 6.4
 7 36 12.0
 >1 Week 33 11.0
 Not reported 12 4.0
Interventions examined: frequencyc
 Serotonin antagonists: reported as administered alone (administered with corticosteroid)
  Ondansetron 115 (69) 38.46 (23.08)
  Granisetron 88 (55) 29.43 (18.39)
  Tropisetron 23 (9) 7.69 (3.01)
  Dolasetron 19 (7) 6.35 (2.34)
  Ramosetron 11 (6) 3.68 (2.01)
  Palonosetron 14 (22) 4.68 (7.36)
 Comparator antiemetics:
  Metoclopramide 21 7.0
  Metoclopramide + steroid 18 6.0
  Steroid 3 1.0
  Chlorpromazine + steroid 2 0.7
  Prochlorperazine 2 0.7
  Azasetron + steroid 1 0.3
  Chlorpromazine 1 0.3
  Metopimazine + steroid 1 0.3
  Prochlorperazine + steroid 1 0.3
 Serotonin antagonists given with other antiemetic:
  Ondansetron + steroid + metoclopramide 6 2.1
  Granisetron + steroid + metoclopramide 6 2.0
  Ondansetron + metoclopramide 2 0.7
  Granisetron + metoclopramide 1 0.4
  Ondansetron + metopimazine 1 0.4
  Tropisetron + metopimazine 1 0.4
  Granisetron + steroid + prochlorperazine 1 0.4
  Ondansetron + steroid + prochlorperazine 1 0.4
  Palonosetron + steroid + prochlorperazine 1 0.4
  Tropisetron + steroid + metoclopramide 1 0.4
  Placebo or no treatment 16 5.67
Outcomes reported: frequencyd
 Nausea 208 69.6
 Vomiting 247 82.6
 CINV 117 39.1
 Arrhythmia 21 7.0
 Delirium 14 4.7
 Mortality 41 13.7
 Sudden cardiac death 3 1.0
 QT interval 25 8.4
Setting
 Multi-center 128 42.8
 Single-center 69 23.1
 Not specified/not reported 101 33.8
  1. CBA controlled before–after, CINV chemotherapy-induced nausea and vomiting, NRCT non-randomized controlled trial, RCT randomized controlled trial
  2. aIncludes unpublished data from conference abstracts and trial protocols (Adel et al. 2006, Tabei et al. 2006, Trifilio et al. 2006, Carreca et al. 2007, Kadota et al. 2007, Piyush 2011)
  3. b Duration is in days unless otherwise noted
  4. c Multiple interventions and comparators examined across the studies
  5. d Multiple interventions and outcomes reported per study